Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (224)	2/20/2001 12:38:48 PM
From: Jim Oravetz	Read Replies (3) \| Respond to of 370

Vion Pharma To Proceed With Anticancer Pdt Phase I Trial Dow Jones Newswires NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc. (VION) said it will begin a Phase I clinical trial of its cancer-fighting agent, VNP40101M, in about two months. In a press release Tuesday, the company said the trial will enroll 20 to 30 patients and will assess the product's safety and maximum dosage. Vion said preclinical studies have shown the agent to be effective at fighting tumors and penetrating the blood brain barrier in mice. Many anticancer agents have difficulty penetrating the brain, a common location of tumors and metastases. Shares of Vion, a biopharmaceutical company, recently traded $6.31, down 63 cents or 9%, on volume of 50,400 shares. Average daily volume is 212,367 shares. Company Web site: vionpharm.com